1 / 8

3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) + RBV in GT1 SAPPHIRE-I

Phase 3. Treatment Naïve. 3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) + RBV in GT1 SAPPHIRE-I. Feld JJ, et al. N Engl J Med. 2014;370:1594-1603. 3D (Paritaprevir-Ritonavir- Ombitasvir + Dasabuvir) + Ribavirin in GT1 SAPPHIRE-I Study : Design.

petronella-meris
Download Presentation

3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) + RBV in GT1 SAPPHIRE-I

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Phase 3 TreatmentNaïve 3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) + RBV in GT1SAPPHIRE-I Feld JJ, et al. N Engl J Med. 2014;370:1594-1603.

  2. 3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) + Ribavirin in GT1SAPPHIRE-I Study: Design Source: Feld JJ, et al. N Engl J Med. 2014;370:1594-1603.

  3. 3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) + Ribavirin in GT1SAPPHIRE-I Study: Study Regimens 0 12 24 36 Week Double blind 3D + Ribavirin Group AN = 473 SVR12 Open label (data pending) Placebo 3D + Ribavirin Group BN = 158 SVR12 3D =Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir Drug Dosing3D = Paritaprevir-Ritonavir-Ombitasvir (150/100/25 mg once daily)+ Dasabuvir: 250 mg twice dailyRibavirin (RBV): weight-based and divided bid (1000 mg/day if < 75kg or 1200 mg/day if ≥ 75kg) Source: Feld JJ, et al. N Engl J Med. 2014;370:1594-1603.

  4. 3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) + Ribavirin in GT1SAPPHIRE-I Study: Baseline Characteristics Source: Feld JJ, et al. N Engl J Med. 2014;370:1594-1603.

  5. 3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) + Ribavirin in GT1SAPPHIRE-I Study: Results SAPPHIRE-I: SVR12 in Group A (3D + Ribavirin) 455/473 307/322 148/151 Source: Feld JJ, et al. N Engl J Med. 2014;370:1594-1603.

  6. NUTRINO: SVR 12 by Liver Disease 3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) + Ribavirin in GT1SAPPHIRE-I Study: Adverse Events During Double-Blind Phase Source: Feld JJ, et al. N Engl J Med. 2014;370:1594-1603.

  7. 3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) + Ribavirin in GT1SAPPHIRE-I Study: Conclusions Note: ABT-450/r = Paritaprevir-Ritonavir Source: Feld JJ, et al. N Engl J Med. 2014;370:1594-1603.

  8. This slide deck is from the University of Washington’s Hepatitis C Online and Hepatitis Web Study projects. Hepatitis C Onlinewww.hepatitisc.uw.edu Hepatitis Web Studyhttp://depts.washington.edu/hepstudy/ Funded by a grant from the Centers for Disease Control and Prevention.

More Related